Page 150 - 2021_04-Haematologica-web

Y. Shi et al.
Blood. 2015;125(19):2958-2967.
16. Serwold T, Hochedlinger K, Swindle J, Hedgpeth J, Jaenisch R, Weissman IL. T-cell receptor-driven lymphomagenesis in mice derived from a reprogrammed T cell. Proc Natl Acad Sci U S A. 2010;107(44):18939- 18943.
17. Palacios EH, Weiss A. Function of the Src- family kinases, Lck and Fyn, in T-cell devel- opment and activation. Oncogene. 2004;23(48):7990-8000.
18. Iwashima M, Irving BA, van Oers NS, Chan AC, Weiss A. Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science. 1994;263(5150):1136-1139.
19. van Oers NS, Killeen N, Weiss A. Lck regu- lates the tyrosine phosphorylation of the T cell receptor subunits and ZAP-70 in murine thymocytes. J Exp Med. 1996;183(3):1053- 1062.
20.Nyakeriga AM, Garg H, Joshi A. TCR- induced T cell activation leads to simultane- ous phosphorylation at Y505 and Y394 of p56(lck) residues. Cytometry A. 2012;81(9):797-805.
21. Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ. Lck is a key tar- get of imatinib and dasatinib in T-cell activa- tion. Leukemia. 2010;24(4):896-900.
22.Di Veroli GY, Fornari C, Wang D, et al. Combenefit: an interactive platform for the analysis and visualization of drug combina- tions. Bioinformatics. 2016;32(18):2866-2868.
23.Harr MW, Caimi PF, McColl KS, et al.
24.
25.
26.
27.
Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Differ. 2010;17(9):1381-1391. Liston DR, Davis M. Clinically relevant con- centrations of anticancer drugs: a guide for nonclinical studies. Clin Cancer Res. 2017;23(14):3489-3498.
Yang L, Panetta JC, Cai X, et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol. 2008;26(12):1932- 1939.
Townsend EC, Murakami MA, Christodoulou A, et al. The Public Repository of Xenografts enables discovery and randomized Phase II-like trials in mice. Cancer Cell. 2016;30(1):183.
Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO; Medical Research Council Childhood Leukaemia Working P. Benefit of dexamethasone com- pared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 random- ized trial. Br J Haematol. 2005;129(6):734- 745.
30.
31.
32.
33.
34.
kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers. PLoS One. 2010;5(11):e14143. Guerrouahen BS, Futami M, Vaklavas C, et al. Dasatinib inhibits the growth of molecu- larly heterogeneous myeloid leukemias. Clin Cancer Res. 2010;16(4):1149-1158. Frismantas V, Dobay MP, Rinaldi A, et al. Ex vivo drug response profiling detects recur- rent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017; 129(11):e26-e37.
Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008;111(3):1366- 1377.
Nerreter T, Distler E, Kochel C, Einsele H, Herr W, Seggewiss-Bernhardt R. Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro. Exp Hematol. 2013;41(7): 604-614.e4.
Smith LK, Cidlowski JA. Glucocorticoid- induced apoptosis of healthy and malignant lymphocytes. Prog Brain Res. 2010;182:1-30.
28.Serafin V, Capuzzo G, Milani G, et al. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lym- phoblastic leukemia. Blood. 2017; 130(25):2750-2761.
29.Kruewel T, Schenone S, Radi M, et al. Molecular characterization of c-Abl/c-Src
35. Slayton WB, Schultz KR, Kairalla JA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children's Oncology Group trial AALL0622. J Clin Oncol. 2018;36(22):2306-2314.
1066
haematologica | 2021; 106(4)